<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093270</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-23339-101</org_study_id>
    <nct_id>NCT05093270</nct_id>
  </id_info>
  <brief_title>First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants</brief_title>
  <official_title>A First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and pharmacokinetics of BGB-23339 and food&#xD;
      effects in healthy participants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes from baseline in vital signs</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
    <description>Vital signs include blood pressure and pulse rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes from baseline in clinical laboratory values</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
    <description>Laboratory values include hematology, clinical chemistry, coagulation, and urinalysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to last quantifiable time (AUClast) for Parts A, B, C and D</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to 24 hours postdose (AUC0-24) for Part D only</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to end of dosing interval (AUCtau) for Parts A, B, C and D</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity (AUCinf) for Parts A, B, C, and D</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) for Parts A, B, C and D</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) for Parts A, B, C and D</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration (Ctrough) for Parts A, B, and C</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life (t½) for Parts A, B, C and D</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
    <description>in fed and fasted states for BGB-23339</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent systemic clearance (CL/F) for Parts A, B, and C</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F) for Parts A, B, and C</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratios, and metabolite to parent ratio for BGB-23339 and its metabolite BGB-25808 as appropriate for Parts A, B, C and D</measure>
    <time_frame>Up to approximately 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Not Determined</condition>
  <arm_group>
    <arm_group_label>Part A Dose Escalation (Single Ascending Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 5 dose levels of BGB-23339 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Dose Escalation (Multiple Ascending Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 4 dose levels of BGB-23339 or placebo based on data collected in Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Dose Escalation (Multiple Ascending Dose in Chinese Subjects Sub-study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 2 dose levels of BGB-23339 or placebo based on data collected in Part A and B (conducted in China only)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D (Food-Effect Study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three single dose levels of BGB-23339 under different feeding conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-23339</intervention_name>
    <description>Administered orally as a tablet</description>
    <arm_group_label>Part A Dose Escalation (Single Ascending Dose)</arm_group_label>
    <arm_group_label>Part B Dose Escalation (Multiple Ascending Dose)</arm_group_label>
    <arm_group_label>Part C Dose Escalation (Multiple Ascending Dose in Chinese Subjects Sub-study)</arm_group_label>
    <arm_group_label>Part D (Food-Effect Study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally as a tablet</description>
    <arm_group_label>Part A Dose Escalation (Single Ascending Dose)</arm_group_label>
    <arm_group_label>Part B Dose Escalation (Multiple Ascending Dose)</arm_group_label>
    <arm_group_label>Part C Dose Escalation (Multiple Ascending Dose in Chinese Subjects Sub-study)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form (ICF) and able to comply with study requirements&#xD;
&#xD;
          2. Healthy men and/or women of no childbearing potential of age ≥ 18 years and ≤ 55 years&#xD;
             on the day of signing the ICF (or the legal age of consent) for Parts A, B and D; of&#xD;
             age≥ 18 years and ≤ 45 years on the day of signing the ICF (or the legal age of&#xD;
             consent) and of Chinese descent for Part C&#xD;
&#xD;
          3. Participants are in good general health as determined by the investigator or medically&#xD;
             qualified designee, based on a medical evaluation including medical history, physical&#xD;
             examination, laboratory tests and cardiac monitoring&#xD;
&#xD;
          4. Body weight ≥ 50 kg and body mass index (BMI) within the range 18 to 32 kg/m2&#xD;
             (inclusive)&#xD;
&#xD;
          5. A nonsterile man with a female partner of childbearing potential must be willing to&#xD;
             use a highly effective method of birth control from the time of study enrollment until&#xD;
             90 days after the last dose of study drug&#xD;
&#xD;
          6. A woman of no childbearing potential must meet at least one of the following criteria:&#xD;
&#xD;
               1. Postmenopausal status, defined as: cessation of regular menses for ≥ 12&#xD;
                  consecutive months (menopause confirmed by Follicular Stimulating Hormone [FSH]&#xD;
                  levels and Luteinizing Hormone [LH] levels as defined by the established&#xD;
                  reference ranges)&#xD;
&#xD;
               2. Surgically sterile (eg, hysterectomy, oophorectomy, or tubal ligation for at&#xD;
                  least the past 3 months).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,&#xD;
             endocrinological, hematological, or neurological disorders capable of significantly&#xD;
             altering the absorption, metabolism, or elimination of drugs; constituting a risk when&#xD;
             taking the study drug; or interfering with the interpretation of data&#xD;
&#xD;
          2. Abnormal blood pressure as determined by the investigator&#xD;
&#xD;
          3. Active herpes infection, including herpes simplex 1 and 2 and herpes zoster&#xD;
             (demonstrated on physical examination and/or medical history ≤ 2 months before&#xD;
             randomization)&#xD;
&#xD;
          4. Any malignancies within the past 5 years except for basal cell or squamous epithelial&#xD;
             carcinomas of the skin that have been resected with no evidence of metastatic disease&#xD;
             for 3 years&#xD;
&#xD;
          5. Past or intended use of prescription medication ≤ 14 days and over-the-counter (OTC)&#xD;
             medication including herbal, vitamins and dietary supplements ≤ 7 days before&#xD;
             randomization&#xD;
&#xD;
          6. Live vaccine ≤ 30 days, and/or vaccine of any type ≤ 14 days before randomization&#xD;
&#xD;
          7. Has received an investigational product within the following time before&#xD;
             randomization: 3 months, 5 half-lives, or twice the duration of the biological effect&#xD;
             of the investigational product (whichever is longer)&#xD;
&#xD;
          8. Participation in a prior study that would result in loss of blood or blood products in&#xD;
             excess of 500 mL within 56 days before randomization&#xD;
&#xD;
          9. Exposure to ≥ 4 new chemical entities within 12 months before randomization&#xD;
&#xD;
         10. Presence of hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody&#xD;
             (HBcAb) at screening or ≤ 3 months before randomization&#xD;
&#xD;
         11. Regular alcohol consumption ≤ 3 months before randomization&#xD;
&#xD;
         12. Regular use of recreational drugs&#xD;
&#xD;
         13. Current use and/or has used nicotine or nicotine-containing products (eg, nicotine&#xD;
             patch and electronic cigarette) within 14 days before randomization&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1-877-828-5568</phone>
    <email>ClinicalTrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nucleus Network Pty Ltd</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

